Kane Biotech Publishes Revyve Wound Gel Study in International Journal

The article highlights the antimicrobial and antibiofilm properties of the company's revyve wound gel.

Feb. 28, 2026 at 4:55pm

Got story updates? Submit your updates here. ›

Kane Biotech Inc. has announced the publication of an article on its revyve Antimicrobial Wound Gel in the peer-reviewed International Wound Journal. The article, co-authored by researchers from the University of Miami, details the gel's efficacy against a broad range of wound-related pathogens, its sustained antimicrobial activity for up to 7 days, and its safety and non-cytotoxicity validated through biocompatibility testing and a porcine wound-healing study.

Why it matters

The publication in the respected International Wound Journal provides independent, peer-reviewed validation of the scientific rigor behind revyve technology and its potential to improve wound care outcomes by disrupting biofilms and reducing antibiotic resistance. This strengthens Kane Biotech's credibility with clinicians, regulators, and commercial partners as the company commercializes its novel wound care treatments.

The details

The key findings from the article include: the thermo-reversible gel shifts from a low viscosity liquid to a form-fitting gel at body temperature, then re-liquefies when cooled for easy, atraumatic removal; revyve demonstrated efficacy against a broad range of wound-related pathogens, including Staphylococcus aureus and Pseudomonas aeruginosa, with a 99.99%–99.9999% reduction in bacterial counts within 30 minutes; and there was sustained in vitro activity for up to 7 days, potentially reducing the number of dressing changes. The safety and non-cytotoxicity of the gel were also validated.

  • The article was published on February 20, 2026.

The players

Kane Biotech Inc.

A company commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes.

Dr. Jeyachchandran Visvalingam

The Internal R&D Leader at Kane Biotech and first author of the published article.

Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery, University of Miami

The department at the University of Miami that collaborated with Kane Biotech on the published article.

Dr. Robert Huizinga

The Interim CEO of Kane Biotech.

Ray Dupuis

The Chief Financial Officer of Kane Biotech.

Got photos? Submit your photos here. ›

What they’re saying

“Having our research published in the International Wound Journal underscores the scientific rigor behind revyve technology and provides independent, peer-reviewed validation of the gel's safety, in vitro performance and clinical potential.”

— Dr. Robert Huizinga, Interim CEO, Kane Biotech Inc. (Kane Biotech Press Release)

What’s next

The company plans to continue commercializing its revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray, and revyve Antimicrobial Skin and Wound Cleanser, all of which are U.S. FDA 510(k) cleared and Health Canada approved.

The takeaway

The publication of Kane Biotech's revyve wound gel research in the prestigious International Wound Journal provides scientific validation of the product's antimicrobial and antibiofilm properties, which could help improve wound care outcomes and reduce antibiotic resistance, a growing concern in the medical community.